Gemzar 200 mg/vial (IV Infusion)

Title and Categories

• Gemzar
• Cytotoxic Chemotherapy

Indications

• Non-Small Cell Lung Cancer
• Pancreatic Cancer
• Bladder Cancer
• Breast Cancer
• Ovarian Cancer

Dosage and Administration

• Single-agent Use
• Combination Use
• Recommended Dose
• Intravenous Infusion
• Cycle Duration
• Dosage Reduction
• Metastatic Adenocarcinoma
• Refractory Pancreatic Cancer

Pharmacology

• Metabolism
• Active Nucleoside
• Cytotoxic Action
• Inhibition of DNA Synthesis
• Inhibition of Ribonucleotide Reductase

Interaction

• No confirmed interactions reported
• No specific drug interaction studies conducted

Contraindications

• Known Hypersensitivity to Gemcitabine
• Hypersensitivity to any other components of this product

Side Effects

• Haematological Toxicity
• Leukopenia
• Thrombocytopenia
• Hepatic Toxicity
• Gastrointestinal Effects
• Genito-Urinary Toxicity
• Pulmonary Toxicity
• Allergic Toxicity
• Neurotoxicity
• Alopecia

Pregnancy & Lactation

• Pregnancy Category D
• Use during pregnancy, excretion in human breast milk unknown

Precautions & Warnings

• Schedule-dependent Toxicity
• Myelosuppression
• Pulmonary Toxicity and Respiratory Failure
• Hemolytic Uremic Syndrome
• Hepatic Toxicity
• Embryofetal Toxicity
• Radiation Therapy Toxicity
• Impairment of Fertility

Use in Special Populations

• Elderly Patients
• Renal and Hepatic Impairment
• Children

Overdose Effects

• No known antidote for overdoses
• Myelosuppression
• Paresthesias
• Severe Rash
• Supportive Therapy

Storage Conditions

• Store in original carton
• Temperature Range 20°C to 25°C
• Protection from light
• Avoid refrigeration

Mode of Action

• Inhibition of RNA
• Induction of Apoptosis
• DNA Polymerase Inhibition
• Self-potentiation
• Cellular Death Process

Pediatric Uses

• Limited Phase I and II Trials
• Efficacy and Safety

Drug Classes

• Cytotoxic Chemotherapy

Related Brands